English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Objectives  The single‐tablet regimen rilpivirine, emtricitabine and tenofovir alafenamide ( RPV / FTC / TAF ) for treatment of  HIV ‐1‐infected adults was approved based on bioequivalence. We assessed the clinical efficacy, safety and tolerability of switching to  RPV / FTC / TAF  from either  RPV / FTC /tenofovir disoproxil fumarate ( TDF ) or efavirenz ( EFV )/ FTC / TDF .    Methods  We conducted two distinct randomized, double‐blind, active‐controlled, noninferiority trials in participants taking  RPV / FTC / TDF  (Study 1216) and  EFV / FTC / TDF  (Study 1160). Each study randomized virologically suppressed ( HIV ‐1  RNA  < 50 copies/ mL ) adults (1:1) to switch to  RPV / FTC / TAF  or continue their current regimen for 96 weeks. We evaluated efficacy as the proportion with  HIV ‐1  RNA  < 50 copies/ mL  using the Food and Drug Administration snapshot algorithm and prespecified bone and renal endpoints at week 96.    Results  We randomized and treated 630 participants in Study 1216 ( RPV / FTC / TAF,   n  = 316;  RPV / FTC / TDF ,  n  = 314) and 875 in Study 1160 ( RPV / FTC / TAF ,  n  = 438;  EFV / FTC / TDF,   n  = 437). In both studies, the efficacy of switching to  RPV / FTC / TAF  was noninferior to that of continuing baseline therapy at week 96, with respective percentages of patients with HIV RNA < 50 copies/ mL  being 89.2% versus 88.5% in Study 1216 [difference 0.7%; 95% confidence interval ( CI ) −4.3 to +5.8%] and 85.2% versus 85.1% in Study 1160 (difference 0%; 95%  CI  −4.8 to +4.8%). No participant on  RPV / FTC / TAF  developed treatment‐emergent resistance versus two on  EFV / FTC / TDF  and one on  RPV / FTC / TDF . Compared with continuing baseline therapy, significant improvements in bone mineral density and renal tubular markers were observed in the  RPV / FTC / TAF  groups ( P  < 0.001).    Conclusions  Switching to  RPV / FTC / TAF  from  RPV / FTC / TDF  or  EFV / FTC / TDF  was safe and effective and improved bone mineral density and renal biomarkers up to 96 weeks with no cases of treatment‐emergent resistance.

hiv medicine

Switching to coformulated rilpivirine ( RPV ), emtricitabine ( FTC ) and tenofovir alafenamide from either  RPV ,  FTC  and tenofovir disoproxil fumarate ( TDF ) or efavirenz,  FTC  and  TDF : 96‐week results from two randomized clinical trials